Get the Stockscreener App
18.44
3.40%
-0.65
Relay Therapeutics Inc stock is traded at $18.44, with a volume of 2.04M.
It is down -3.40% in the last 24 hours and up +2.33% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$19.09
Open:
$19.18
24h Volume:
2.04M
Relative Volume:
0.52
Market Cap:
$4.02B
Revenue:
$10.68M
Net Income/Loss:
$-272.71M
P/E Ratio:
-11.78
EPS:
-1.565
Net Cash Flow:
$-213.38M
1W Performance:
-7.38%
1M Performance:
+2.33%
6M Performance:
+148.18%
1Y Performance:
+401.09%
1-Day Range:
$18.26
$19.29
1-Week Range:
$18.26
$20.39
52-Week Range:
$3.025
$20.79
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
18.44 | 4.02B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics Inc (RLAY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Relay Therapeutics Inc (RLAY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Relay Therapeutics Inc (RLAY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Relay Therapeutics Inc (RLAY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Relay Therapeutics (RLAY) insider plans sale of 30,000 shares after option exercise - Stock Titan
RLAY Maintained by Goldman Sachs -- Price Target Raised to $31 - GuruFocus
Relay Therapeutics stock trades around recent lows as cash burn and pipeline data shape the outlook - AD HOC NEWS
Relay Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
Certain Stock Options of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Why Is RLAY Stock Rising Today? - Stocktwits
Canaccord initiates Relay Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Relay Therapeutics (RLAY) Edges Higher as Stock Tests Key Resistance at $20.68High Volume Stocks - dars.gov.et
Canaccord initiates Relay Therapeutics stock with buy rating - Investing.com
RLAY Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29 - Moomoo
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Relay Therapeutics Inc. (RLAY) Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Waits - Bölüm Sonu Canavarı
Relay Therapeutics president sells $162,028 in company stock - Investing.com UK
Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing - Moomoo
Insider Sell Alert: Donald Bergstrom Sells Shares of Relay Thera - GuruFocus
Form 4 Relay Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock - Investing.com Nigeria
Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade - Stock Titan
Relay Therapeutics CFO Thomas Catinazzo sells $331,130 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics president sells $162,028 in company stock By Investing.com - Investing.com UK
Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings - Stock Titan
CFO at Relay Therapeutics (RLAY) sells shares under Rule 10b5-1 plan - Stock Titan
Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next - simplywall.st
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating By Investing.com - Investing.com Nigeria
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating - Investing.com
Form 144 RELAY THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
Relay Therapeutics stock hits 52-week high at 19.97 USD By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week high at 19.97 USD - Investing.com
Enterprise value to revenue forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Enterprise value to EBIT forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Price to sales forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Price to earnings forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Relay Therapeutics (RLAY) Gains Modestly as Trading Volume Picks UpNAAIM Exposure - dars.gov.et
Price to book forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
RLAYRelay Therapeutics Inc Latest SEC Filings - Finviz
Insider Sell: Peter Rahmer Sells 50,000 Shares of Relay Therapeu - GuruFocus
Relay Therapeutics (RLAY) exec ESPP buy, 50K-share 10b5-1 sale - Stock Titan
Relay Therapeutics (RLAY) Joins Multiple Russell Growth Indexes Is Its Biotech Role Being Repriced? - simplywall.st
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):